Drug Profile
FCARH 143
Alternative Names: Autologous anti-BCMA-CAR-expressing CD4+/CD8+ T lymphocytes - Juno Therapeutics; BCMA CAR-CD4+/CD8+ T cells; BCMA-specific CAR-expressing CD4+/CD8+ T lymphocytes; FCARH143Latest Information Update: 17 Aug 2022
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Juno Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 22 Mar 2022 Juno Therapeutics and Fred Hutchinson Cancer Research Center completes a phase I trial for Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03338972)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA (IV, Infusion)